In 2017, Domain Therapeutics signed a master innovative and scientific partnership agreement with 5 SATT (Société d’Accélération et de Transfert de Technologies) in France to source valuable assets from academics and universities.

This agreement will allow Domain to identify additional assets from Aquitaine Science Transfert, Conectus Alsace, Ouest Valorisation, SATT Sud-Est and Toulouse Tech Transfer to extend its portfolio of drug candidate in the field of interest of Domain. Most promising discovery projects will benefit from Domain business model and expertise to be progress through an asset centric company up to the clinic (see press release).